September 18, 2026

Novo + Orbis $1.4B Oral Macrocycle Deal, Novo Capital Markets Day Preview, Roche Lunsumio CELESTIMO Phase 3 Hit

Novo bets $1.4B on Orbis oral macrocycles, Roche Lunsumio CELESTIMO Phase 3 hits, Halozyme upsized $1.3B notes, Novo Capital Markets Day preview.

7 stories · Covering industry, clinical-trials, regulatory, research

Editor's Note

Friday's deal sheet centered on Novo's $1.4 billion oral-macrocycle collaboration with Copenhagen-based Orbis Medicines, announced Thursday September 17 and syndicated through Friday. The pact deploys Novo's cardiometabolic capital against Orbis's nGen AI-driven macrocyclic-peptide platform in the search for orally bioavailable versions of targets historically requiring injection — a category that includes GLP-1 receptor agonism itself, though neither company named specific targets. The agreement is the young biotech's first Big Pharma partnership since its January 2025 $93 million Series A, and lands two working days ahead of Novo's Monday September 21 Capital Markets Day in London, where CEO Mike Doustdar is expected to reframe the company under its new 'Novo' brand identity for the first time since taking the top job. Elsewhere Roche's Lunsumio (mosunetuzumab, CD20xCD3 bispecific antibody) + lenalidomide combination hit its progression-free-survival primary endpoint in the Phase 3 CELESTIMO trial in relapsed/refractory follicular lymphoma. Halozyme priced an upsized $1.3 billion convertible-notes offering to refinance 2027-2028 maturities and fund ENHANZE platform expansion, and Bristol Myers Squibb ended its ORM-6151 CD33 degrader-antibody conjugate collaboration with Orum Therapeutics after Phase 1 data, extinguishing $80 million in remaining milestones. Nuvation Bio secured an FDA label update for IBTROZI (taletrectinib) in ROS1-positive NSCLC citing 49.7-month median duration of response, and a Healthline-published research analysis of real-world sustained low-dose GLP-1 use found average one-year weight loss of 5.5% on tirzepatide and 2.2% on semaglutide.

Industry

Novo Signs $1.4 Billion Deal With Orbis Medicines for AI-Designed Oral Macrocyclic Peptides Targeting Cardiometabolic Diseases; nGen Platform Backed by 18% Oral Bioavailability Preclinical Signal

Novo (formerly Novo Nordisk) and Copenhagen-based Orbis Medicines announced Thursday September 17, 2026 a multi-target drug discovery and licensing collaboration under which Orbis will apply its proprietary nGen macrocyclic-peptide platform — an integration of generative AI, high-throughput synthesis, and multi-parameter optimization for oral bioavailability — to design next-generation oral macrocycles for high-value cardiometabolic disease targets. Orbis is eligible for up to $1.4 billion in upfront and downstream milestone payments plus tiered royalties on future product sales, and Novo will make a separate strategic equity investment in Orbis. Orbis founding CEO Morten Graugaard disclosed the platform's macrocyclic peptides have achieved up to 18% oral bioavailability in preclinical models — a notable improvement for the macrocycle class that has historically struggled with gut absorption. Orbis was founded in January 2025 with a $93 million Series A led by Novo Holdings and Forbion; the Novo pact is the young biotech's first Big Pharma partnership. Neither company disclosed specific targets or lead candidates. The deal deepens Novo's oral-peptide investment strategy following the January 2026 Wegovy pill launch (now surpassing 5 million U.S. prescriptions) and lands the same week the parent company introduced its shorter 'Novo' operating brand.

#novo-nordisk #novo #nvo #orbis-medicines #1-4-billion-deal #oral-macrocyclic-peptides #ngen-ai-platform #cardiometabolic-diseases #novo-holdings-forbion-series-a #18-percent-oral-bioavailability #first-big-pharma-pact #macrocycle-drug-discovery #danish-biotech #peptide

Industry

Novo Capital Markets Day Set for Monday September 21 in London; First Under CEO Mike Doustdar and Under the New 'Novo' Operating Brand

Novo (formerly Novo Nordisk; NYSE: NVO; Copenhagen: NOVO-B) confirmed the Capital Markets Day will be held Monday September 21, 2026 in London, webcast live starting 09:00 BST / 10:00 CEST. The event is the first Capital Markets Day under CEO Mike Doustdar and the first outing under the rebranded 'Novo' identity introduced Monday September 14 with the tagline 'Lasting health starts now' and 'The Novo Way' culture framework. Sell-side previews (TIKR, Bloomberg, Kontra Invest) frame the event as a critical reset opportunity following the Friday September 11 Morgan Stanley Underweight downgrade (DKK 250 target), Barclays trim to DKK 300, and HSBC target raise to DKK 320 (Hold). Novo shares trade approximately 32% below the January 2026 52-week high of EUR 54.86. Priorities investors want addressed: the semaglutide 2031 loss of exclusivity, U.S. Wegovy pill script momentum (surpassing 5 million total prescriptions by August), CagriSema's late-2026 U.S. obesity decision path, the ziltivekimab HERMES + ATHENA heart-failure terminations, and how Wednesday's Anthropic Claude Science R&D collaboration and Thursday's $1.4 billion Orbis Medicines macrocycle deal fit the reset narrative.

#novo-nordisk #novo #nvo #capital-markets-day-london-september-21 #mike-doustdar-ceo #morgan-stanley-underweight-context #2031-semaglutide-loss-of-exclusivity #wegovy-pill-5-million-prescriptions #cagrisema-late-2026-decision #ziltivekimab-terminations-context #anthropic-claude-context #orbis-medicines-context #glp-1

Clinical Trials

Roche Lunsumio (Mosunetuzumab, CD20xCD3 Bispecific Antibody) Plus Lenalidomide Meets Progression-Free-Survival Primary Endpoint in Phase 3 CELESTIMO Trial in Relapsed/Refractory Follicular Lymphoma

Roche (SIX: ROG; OTCQX: RHHBY) announced Thursday September 17, 2026 that the Phase 3 CELESTIMO trial evaluating Lunsumio (mosunetuzumab, an anti-CD20 x anti-CD3 T-cell-engaging bispecific antibody) plus lenalidomide versus MabThera/Rituxan (rituximab) plus lenalidomide (R2 regimen) in adults with relapsed or refractory follicular lymphoma (R/R FL) who received at least one prior line of treatment met its primary endpoint, showing a statistically significant improvement in progression-free survival (PFS). Overall survival data were immature at the interim analysis. The safety profile of the Lunsumio + lenalidomide combination was consistent with the known profiles of the individual agents, with no new safety signals. Data will be submitted to global health authorities and presented at an upcoming medical meeting. Lunsumio was FDA-approved in December 2022 for third-line-plus R/R FL as a monotherapy; a positive earlier-line CELESTIMO readout positions the drug to challenge the R2 standard-of-care regimen in second-line R/R FL, an approximately $1 billion sales opportunity in the U.S. alone.

#roche #rog #rhhby #lunsumio #mosunetuzumab #cd20xcd3-bispecific-antibody #t-cell-engager #lenalidomide #celestimo-phase-3 #relapsed-refractory-follicular-lymphoma #pfs-primary-endpoint-met #second-line-fl #r2-standard-of-care-challenge #non-peptide

Industry

Halozyme Prices Upsized $1.3 Billion 1.50% Convertible Senior Notes Due 2033 Offering to Refinance 2027-2028 Maturities and Fund ENHANZE Recombinant Hyaluronidase (rHuPH20) Platform Expansion

Halozyme Therapeutics (NASDAQ: HALO) priced Thursday September 17, 2026 an upsized $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 — increased from the previously announced $1.05 billion offering size announced Wednesday September 16, 2026. Terms: 1.50% coupon, semi-annual interest, initial conversion rate of 7.1509 shares per $1,000 principal (approximately $139.84 per share initial conversion price). Halozyme will use approximately $652.5 million of proceeds to repurchase existing convertible notes maturing in 2027 and 2028; the balance funds general corporate purposes including working capital and potential acquisitions. Offering close targeted September 22, 2026. Halozyme is the innovator of the ENHANZE recombinant hyaluronidase drug-delivery technology (proprietary rHuPH20 enzyme), which enables subcutaneous conversion of intravenously administered biologics — deployed by 10+ marketed products across partners including Roche (Herceptin SC, Phesgo, Ocrevus Zunovo, Tecentriq Hybreza), J&J (Darzalex Faspro, Rybrevant SC), Bristol Myers Squibb (Opdivo Qvantig), argenx (Vyvgart Hytrulo), and Alteogen's competing ALT-B4 platform after Roche's separate September 8 Alteogen licensing deal.

#halozyme-therapeutics #halo #1-3-billion-convertible-notes #upsized-offering #1-50-percent-coupon #notes-due-2033 #enhanze-platform #rhuph20-recombinant-hyaluronidase #subcutaneous-conversion #652-million-refinancing #roche-partner #jnj-partner #bristol-myers-squibb-partner #argenx-partner #alteogen-context #recombinant-enzyme

Regulatory

Nuvation Bio Secures FDA Label Update for IBTROZI (Taletrectinib) in ROS1-Positive Advanced NSCLC Citing 49.7-Month Median Duration of Response in TRUST-I TKI-Naive Population After 51 Months of Follow-Up

Nuvation Bio (NYSE: NUVB) announced Thursday September 17, 2026 an FDA label update for IBTROZI (taletrectinib, next-generation ROS1 tyrosine kinase inhibitor with intracranial and G2032R-resistance-mutation activity) in adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). The updated label incorporates 51-month follow-up data from the Phase 2 TRUST-I trial in ROS1-TKI-naive patients: median duration of response 49.7 months (4+ years), a durability benchmark that has not previously been reported in this population. IBTROZI was FDA-approved in June 2025 for TKI-naive and TKI-pretreated ROS1+ metastatic NSCLC based on ORR and DOR from TRUST-I and TRUST-II. Taletrectinib is co-developed with Innovent Biologics in Greater China. The label update lands two months after competitor Nuvalent's zidesamtinib (Jideytro, GSK) received FDA approval July 22, 2026 for TKI-pretreated ROS1+ NSCLC ahead of its Friday September 18 PDUFA action date, setting up a two-way durability contest in the ROS1+ NSCLC market.

#nuvation-bio #nuvb #ibtrozi #taletrectinib #ros1-tyrosine-kinase-inhibitor #ros1-positive-nsclc #trust-i-51-month-follow-up #49-7-month-median-dor #innovent-biologics #zidesamtinib-competitor-context #nuvalent-gsk-context #non-peptide

Industry

Bristol Myers Squibb Ends ORM-6151 CD33 Degrader-Antibody Conjugate Collaboration With Orum Therapeutics After Phase 1 Data Review; $80 Million in Remaining Milestone Obligations Extinguished, Original $100 Million Upfront Retained

Bristol Myers Squibb (NYSE: BMY) informed Seoul-based Orum Therapeutics on Wednesday September 16, 2026 (disclosed publicly Thursday September 17) that it would end its development program for BMS-986497 (ORM-6151) — a CD33-targeting degrader-antibody conjugate (DAC) combining an anti-CD33 monoclonal antibody with a GSPT1 protein-degrader payload for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes — after reviewing Phase 1 clinical data. BMS acquired the asset in October 2023 for $100 million upfront against a total deal value of up to $180 million; today's termination extinguishes the remaining $80 million in milestone obligations while Orum retains the original $100 million upfront. Orum plans to analyze the discontinuation rationale to inform its lead candidate ORM-1153, a next-generation hematologic-cancer DAC nearing Phase 1 initiation in the United States. The DAC class remains an active industry focus, positioned by boosters as a potential 'post-ADC' modality; the termination extends a difficult stretch for BMS Phase 1 oncology asset walks and marks the third BMS discontinuation of an in-licensed early-stage program this year.

#bristol-myers-squibb #bmy #orum-therapeutics #orm-6151 #bms-986497 #cd33-degrader-antibody-conjugate #gspt1-protein-degrader #dac-modality #acute-myeloid-leukemia #high-risk-mds #phase-1-termination #80-million-milestones-extinguished #orm-1153-next-generation #non-peptide

Research

Healthline Reports on Sustained Low-Dose 'Microdosing' GLP-1 Real-World Analysis: 5.5% Mean Body Weight Loss at 12 Months on Low-Dose Tirzepatide, 2.2% on Low-Dose Semaglutide With Fewer GI Side Effects

Healthline published Friday September 18, 2026 an analysis of an emerging real-world usage pattern in which patients remain on the lowest starting doses of GLP-1 receptor agonists — tirzepatide (Zepbound/Mounjaro) or semaglutide (Wegovy/Ozempic) — for extended periods rather than titrating to full therapeutic doses. The published research summarized in the article: at 12 months, sustained low-dose tirzepatide produced a 5.5% mean body weight reduction, while sustained low-dose semaglutide produced a 2.2% mean reduction. Both figures fall well below full-titration Phase 3 comparators (Wegovy STEP 1 13.7%, SURMOUNT-5 tirzepatide 20.2% at 72 weeks) but sustained low-dose semaglutide was associated with lower rates of nausea, vomiting, and other GI adverse events. The 'microdosing' pattern is not FDA-labeled dosing and reflects patient-and-prescriber choices driven by cost (compounded and telehealth pricing), tolerability, or maintenance-phase preferences. Real-world evidence on the durability of these smaller-than-labeled reductions remains preliminary.

#microdosing-glp-1 #sustained-low-dose #real-world-evidence #tirzepatide-low-dose #semaglutide-low-dose #5-5-percent-tirzepatide #2-2-percent-semaglutide #12-month-outcomes #reduced-gi-side-effects #off-label-dosing-pattern #compounded-context #glp-1 #wegovy #zepbound